The Role of the Omentum in the Treatment of Morbid Obesity

Sponsor
Vanderbilt University Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT00212160
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
66
1
4
81
0.8

Study Details

Study Description

Brief Summary

The purpose of this research is to determine some of the reasons that blood sugar and insulin levels improve after bariatric surgery but before weight loss begins, as well as why people respond differently to weight loss surgery. It will also examine whether removing the fat around the stomach and large intestine (the omentum) will improve weight loss. Finally, it will see why there are differences between Whites and African Americans who have weight loss surgery.

Condition or Disease Intervention/Treatment Phase
  • Procedure: omentectomy
N/A

Detailed Description

The purpose of this research is to tease out the mechanisms related to changes in insulin sensitivity, metabolism, hormones, and body composition following bariatric surgery. Because preliminary data indicate differing responses to this surgery, both Caucasian and African American adults, scheduled for RYGB, are being recruited to participate. It is believed that the omentum contributes to hepatic insulin resistance, both because of the increased delivery of NEFAs via the portal vein, and the increased production of cytokines. Because of this, it is postulated that removing the omentum as part of bariatric surgery will speed up the reversal of insulin resistance and diminish racial differences in response to the surgery.

Data are derived from tissue and blood samples obtained operatively (from individuals having bariatric surgery and other abdominal operations), as well as during hyperinsulinemic-euglycemic clamps, from indirect calorimetry, DEXA, Health-related Quality of Life surveys, and 24-hour urine samples. There were 66 participants randomized to omentectomy/no omentectomy. A post hoc data power analysis determined that this number of subjects is sufficient for data analysis.

Study Design

Study Type:
Interventional
Actual Enrollment :
66 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
The Role of the Omentum in the Treatment of Morbid Obesity
Actual Study Start Date :
Jan 1, 2005
Actual Primary Completion Date :
Oct 1, 2011
Actual Study Completion Date :
Oct 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: RYGB with omentectomy

Subjects undergoing RYGB will be randomized to also have the greater omentum removed at the time of surgery.

Procedure: omentectomy
RYGB with omentectomy

No Intervention: RYGB without omentectomy

Subjects undergoing RYGB will be randomized to NOT have the greater omentum removed at the time of surgery.

No Intervention: Normal body weight

Healthy normal weight subjects studied via hyperinsulinemic-euglycemic clamp to obtain reference values for insulin sensitivity and other metabolic parameters.

No Intervention: Tissue samples

Tissue samples (omental fat, subcutaneous fat, muscle,and blood)are obtained from subjects of varying weights during abdominal surgery in order to compare various parameters, including inflammation, oxidative stress, and gene expression, among tissues across weight classes.

Outcome Measures

Primary Outcome Measures

  1. change in insulin sensitivity [5 year]

Secondary Outcome Measures

  1. Weight loss [5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • BMI > 40

  • BMI > 35 with co-morbidities

  • normal creatinine/liver labs

  • insurance approval for RYGB or resources to self-pay

  • proximity to Nashville, TN

Exclusion Criteria:
  • use of anticoagulants, steroids, therapeutic niacin

  • previous bariatric surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vanderbilt University Medical Center Nashville Tennessee United States 37232

Sponsors and Collaborators

  • Vanderbilt University Medical Center
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

  • Principal Investigator: Naji N Abumrad, MD, Vanderbilt University Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Naji Abumrad, Chairman, Department of Surgery, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier:
NCT00212160
Other Study ID Numbers:
  • IRB #040572
  • R01DK070860
  • 3R01DK070860-01S1
  • NCT00247598
First Posted:
Sep 21, 2005
Last Update Posted:
Feb 1, 2017
Last Verified:
Jan 1, 2017
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 1, 2017